• Silver prices rose by 29% YoY in 2020, led by an 8% increase in physical investment demand
• The World Silver Survey 2021 has forecast total silver demand to rise by 15% in 2021 to 1.03 billion ounces, with industrial silver consumption set to bounce back by 8% YoY
• The rosy demand outlook contrasts against silver’s tenuous supply profile, with annual mining production declining for a fourth consecutive year in 2020
• Excellon Resources is among the leaders in the search for new silver deposits, with a precious metals growth pipeline that includes: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high quality gold development project in Idaho with strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany with 750 years of mining history and no modern exploration

Silver has long been recognized as the world’s best conductor of energy, and electric vehicles as well as solar power-led photovoltaics are set to serve as major demand drivers for the metal over the coming years (https://ibn.fm/nQVtP). Nonetheless, the onset of the pandemic and resulting slowdown in global economic conditions led industrial silver demand to fall by 5% in 2020 to a five-year low of 486.8 million ounces, a decline which was countermanded to a certain extent by a sharp increase in physical investment demand for the precious metal. In fact, investor demand for silver bars and coins rose by 8% last year to a four-year high of 200.5 million ounces. Resurgent industrial demand in 2021, coupled with ongoing physical investment demand, are set to bode positively for companies such as Excellon Resources (TSX: EXN) (NYSE American: EXN) (FSE: E4X2), a silver and base metals producer with precious metal projects in Mexico, Idaho and Germany. The Silver Institute’s World Silver Survey 2021 revealed that silver prices had risen by 27% between 2019 and 2020, with the precious metal trading at an annual average of $20.55 an ounce over the past year. The price rally was largely fueled by a surge of net inflows into silver-backed exchange-traded products (“ETPs”), with investment vehicles seeing underlying holdings of the precious metal rise by 331.1 million ounces over the course of 2020 (https://ibn.fm/LvXzw), taking overall global holdings above one billion ounces for the first time since ETPs were first introduced in 2006. Remarkably, the rise in investment demand came amidst an 85% plunge in Indian silver investment demand, traditionally a mainstay of global investment demand for the precious metal. The World Silver Survey has forecast a rise in total silver demand in 2021 of 15% to 1.03 billion ounces, with industrial demand set to rebound by 8% year-over-year. However, the rosy demand outlook contrasts against the commodity’s rapidly declining supply profile. In 2020, global mine production registered its fourth consecutive annual decline, with silver output declining by 5.9% to 784.4 million ounces. The decline was primarily driven by a reduction in production from primary silver mines. These mines, which accounted for 27% of total silver production last year, saw output fall by 11.9% year-over-year to 209.4 million ounces. This decline was further exacerbated by temporary mine closures across a host of major silver producing countries in the first half of 2020 (https://ibn.fm/C7Bix). An ongoing reduction in global mine output has lent more urgency to the search for fresh silver supplies. Excellon Resources has been a key driver of the movement, currently working towards developing a precious metals growth pipeline across a diverse range of geographies including Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho boasting strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany. A dearth of new silver deposit discoveries, coupled with resurgent industrial and physical investment demand, may eventually lead to a production squeeze for the precious metal. Should that eventuality come to fruition, Excellon Resources looks well positioned to capitalize on it. For more information, visit the company’s website at www.ExcellonResources.com. NOTE TO INVESTORS: The latest news and updates relating to EXN are available in the company’s newsroom at https://ibn.fm/EXN

• Earlier this year, Grapefruit was approached by a Canadian cannabis company about a potential acquisition.
• A series of events have delayed the process.
• Final decisions, details should be discussed in the next 30–60 days.

Grapefruit USA (OTCQB: GPFT), a premiere, fully licensed, California-based cannabis company, is providing clarification regarding its previously announced potential acquisition transaction by a Canadian cannabis company (https://ibn.fm/g8yCF). Earlier this year, Grapefruit announced that it had been approached by a Canadian cannabis company to enter into discussions concerning a potential acquisition transaction (https://ibn.fm/FitM6). At the time, Grapefruit CEO Bradley J. Yourist noted that “Grapefruit is not surprised to be approached concerning a potential acquisition, in light of the company’s recent disclosure concerning its 714% year-over-year revenue increase; the public reaction to the company’s patented, disruptive Hourglass(TM) THC/cannabinoid delivery cream; and recent announcements by U.S. Senate Majority Leader Chuck Schumer concerning prioritization of the federal legalization of cannabis by descheduling THC.” Following that initial announcement, Grapefruit issued a series of follow-up announcements noting further progress of the potential acquisition, including the development of a memorandum of understanding (“MOU”) that sets forth terms under which the parties could enter into a joint venture to jointly manufacture, distribute and market Grapefruit’s products (https://ibn.fm/eLuE5) as well as an announcement that the potential Canadian partner had scheduled a special shareholder’s meeting to consider the proposed joint venture and other corporate matters (https://ibn.fm/maAvq). At the shareholder meeting, the Canadian partner’s shareholders elected new directors and approved the acquisition of a Canadian-based hemp cultivator. Those actions triggered a change in control of the Canadian partner; as a result, the company had to submit new filings to the Canadian Stock Exchange and the formal joint venture agreement and further acquisition discussions were postponed pending acceptance of the filing by the CSE, which the Canadian partner expects in the very near future. “While Grapefruit was, of course, disappointed by the delays occasioned by our counterpart’s corporate action (which were in progress before our discussions commenced), we believe it was in the best long-term interests of Grapefruit and its shareholders to accept a pause while the Canadian partner concluded its corporate actions,” Yourist said. “Now we move forward. “As we have stated before, a joint venture may precede without precluding an acquisition. Execution of the MOU moved the entire process forward, as we now more clearly understand each other’s overall goals and priorities as well as the capital requirements and legal, regulatory and logistical challenges of finalizing a joint venture and/or an acquisition,” Yourist continued. “We expect to bring the process forward to the point of making a decision in the next 30–60 days. Once again, that being said, we wish to emphasize that the discussions reported here, although substantive and largely positive, remain preliminary in nature and may be terminated at any time. Grapefruit will update the public as necessary on any material joint venture or acquisition developments as events proceed.” Grapefruit holds California permits and licenses to both manufacture and distribute cannabis products in the Golden State. The company’s extraction laboratory and manufacturing and distribution facilities are located in the industry-recognized Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, located on the extension of North Canyon Road, approximately 14 miles north of downtown Palm Springs. Grapefruit’s flagship product — Hourglass time-release delivery cream — features cutting-edge science and technology that solve the age-old problem of THC and other cannabinoids not being easily absorbed through the skin. The topical cream uses patented microsized particles to slowly deliver THC and a wide range of cannabinoids through skin topical administration. No other topical cream product on the market provides users with the holistic benefits of the range of cannabinoids found in Hourglass. To find out more about the company and its game-changing Hourglass time-release cannabinoid delivery cream, please visit www.GrapefruitBlvd.com. NOTE TO INVESTORS: The latest news and updates relating to GPFT are available in the company’s newsroom at https://ibn.fm/GPFT

• Sales milestone represents licensees’ ability to successfully support a safe, accessible and effective adult-use industry
• Billion-dollar mark was reached despite 60-day shutdown of recreational cannabis industry due to COVID-19
• Earlier this year, Hero Technologies formed MassCannabis to explore potential opportunities, projects in the state

Late last year, the nonmedical cannabis market in Massachusetts hit a significant milestone: $1 billion in sales since the state voted to legalize the substance — this even though the state was one of only a handful that closed cannabis shops for a period of time because of COVID-19 (https://ibn.fm/HaVli). Sales in the space have continued strong in 2021, and Hero Technologies (OTC: HENC) is strengthening its position in the state through its new wholly owned subsidiary, MassCannabis LLC. “According to the Cannabis Control Commission, 80 Massachusetts marijuana retailers, as of Oct. 30, reported $1,000,521,905 in sales since stores opened in November 2018,” reported the “Boston Business Journal,” which noted that the sales milestone represents licensees’ ability to successfully support a safe, accessible and effective adult-use industry as well as resulting tax benefits that will have a significant impact on communities throughout the commonwealth. “‘These numbers also speak to commission licensing and enforcement staff working around the clock to make sure these businesses and their products comply with all of our regulations, especially the health and safety provisions,” said Commission Chairman Steven J. Hoffman in the article. The article also observed that the milestone was reached despite a 60-day shutdown of the recreational cannabis industry earlier this year due to the coronavirus. “Through June, the state had reported $122 million in tax revenue,” stated the article. “At $1 billion in sales, the state is on pace to collect $200 million in taxes for the state and local municipalities. Revenue comes from a 6.25% sales tax, a 10.75% excise tax, and local option tax for cities and towns, up to 3%.” The article also noted that the sales come from 97,412 different products. With the potential of the Massachusetts market in mind, Hero Technologies announced in March that it had formed a subsidiary, MassCannabis, to seek property or land acquisition opportunities in the state of Massachusetts as well as potentially initiate dispensary projects (https://ibn.fm/GE4fk). “In forming our new MassCannabis subsidiary, we have taken another key step in executing our growth strategy as a multi-state operator (‘MSO’) and diversified our vertically integrated business model,” said Hero Technologies CEO Gina Serkasevich. “Massachusetts is clearly a fast-growing cannabis market, and expanding our footprint there would extend our geographical reach in the U.S. and diversify our addressable market.” With U.S. and Massachusetts numbers showing significant growth, Hero Technologies appears to be ideally positioned in the burgeoning market. “We are growers and cultivators, developers, builders, engineers, marketers, and managers all here to serve Hero Technologies Inc. as we rapidly develop the largest vertically integrated cannabis company the world has ever known,” the company website proclaims (https://ibn.fm/xYP6Y). And while that statement may seem lofty, a closer look at the company reveals a portfolio of companies that provide superior cultivation and dispensary assets. HENC’s portfolio includes a majority stake in BlackBox Systems and Technologies LLC., an aeroponic cannabis cultivation system that provides optimal conditions to enhance photosynthesis and cultivation of large flowering plants, creating increased efficiencies. In addition to its expansion into Massachusetts, Hero Technologies is planning expansion in cultivation and dispensary operations into Colorado through its wholly owned subsidiary Mile High Green LLC. Hero Technologies Inc. is a cannabis company working toward a vertically integrated business model. The company’s strategic business plan includes cannabis genetic engineering, farmland for both medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, and retail and dispensary operations that make the company a multistate operator. For more information, visit the company’s website at www.HeroTechnologiesInc.com. NOTE TO INVESTORS: The latest news and updates relating to HENC are available in the company’s newsroom at https://ibn.fm/HENC

• Venus Williams has demonstrated that a plant-based lifestyle can bring health benefits even for those with a physically demanding lifestyle, such as high-performance athletes
• PlantX and Williams teamed up to help company’s community adopt and maintain a plant-based lifestyle
• PlantX committed to becoming a plant-based market leader; demonstrates the ability to engage influential public figures and create a community around wholesome, healthy living

Collaboration between PlantX Life (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) and Venus Williams is one of the powerful alignment of core values. As someone who has overcome considerable health barriers in her sports journey with the help of a vegan diet, she is a natural fit for PlantX as a company dedicated to making plant-based living accessible to consumers. Today, Venus Williams is one of the most accomplished tennis players in the history of the sport. But ten years ago, this remarkable athlete was diagnosed with Sjögren’s syndrome, an autoimmune disease causing joint pain and fatigue that forced her to pause playing tennis. To ease debilitating symptoms and take back control of her health, she overhauled her nutrition embracing plant-based nutrition. It turned out that the decision to fuel her body with a plant-based diet was right. After only ten months, she recovered and won her 5th Wimbledon Championship and an Olympic Gold medal. (https://ibn.fm/qPw5L). Being a company committed to providing holistic access to plant-based living for consumers in North America, PlantX teamed up with this world-renowned athlete to help consumers embark on a plant-based journey which can sometimes feel overwhelming. As a result of this collaboration, a new PlantX online hub was born to showcase the company’s plant-based products carefully selected and curated by the world-famous tennis champion and entrepreneur. Williams has also become a PlantX Ambassador leveraging the company’s platform to advocate for the benefits of living a plant-based lifestyle and increase awareness of PlantX’s product offerings by promoting it to her audiences and a considerable following across her personal platforms (https://ibn.fm/2N8Tv). The dedicated section on the PlantX website, named “Venus’ Favorites,” serves as a hub where this tennis superstar shares her plant-based ideas and tips and enhances awareness and education about wholesome, healthy living that can improve sports performance (https://ibn.fm/5X1j7). The section features categories such as Venus’ Top 10 Pantry Picks, Venus’ Favorite Supplements, Venus’ Favorite Plant-Based Products and Venus’ Favorite Products For Recovery. Pantry Picks category involves products such as Alter Eco, Red Heirloom Quinoa, Westbrae Black Lentils or Earth Balance Coconut and Peanut Spread. The supplements category includes brands such as Plant Fusion, Organic India, Goli Nutrition, Sun Potion and Goldthread, offering consumers a broad range of premium products intended for optimal performance and overall wellness. Venus’ Favorite Plant-Based Products curate the list of her favorite items both for consumers and their pets. It includes brands such as Sunfood Superfood, Smart Sweets, Lenny and Larry’s Protein Cookie, Endangered Species, Pacific Food, Rao and V Dog. The recovery range includes premium products from Recover 180, Traditional Medicinals, Zola Coconut Water and Mud/Wtr. Since she overhauled her nutrition a decade ago, Williams has become a vegan icon advocating the health benefits of a plant-based lifestyle in sports performance and beyond. With her considerable experience in transitioning to a plant-based diet, she is well-placed to encourage people to learn more about this lifestyle and educate them on how to integrate this healthy lifestyle into their own lives. This makes the world-famous tennis superstar a natural fit for PlantX as a company committed to empowering consumers to make a positive lifestyle change to help them live healthier and happier lives. With this move, the company has demonstrated again the ability to engage inspiring influential figures and create an ecosystem around wholesome, healthy living. For more information, visit the company’s website at www.Investor.PlantX.com, and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• Decision represents opportunity to help millions suffering from social, generalized anxiety disorders
• Global markets will reach an estimated $4 billion this year, with significant growth projected looking forward
• WHO estimates that 1 in 13 adults globally suffer from anxiety; treatment options have slow onset, undesirable side effects

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has identified social anxiety disorder, or SAD, and generalized anxiety disorder, or GAD, as the initial target indications for its proprietary psychedelic molecule CYB004 (https://ibn.fm/BQdjY). Collectively, the two global markets will reach an estimated $4 billion this year, with significant growth projected looking forward. “The decision to pursue anxiety-disorder indications for CYB004 follows months of thoughtful, in-depth work by the Cybin development team,” said Cybin CEO Doug Drysdale. “Careful consideration of many factors drives these decisions, including the prevalence of anxiety disorders, the measurable clinical endpoints, a realistic preclinical and clinical plan, along with an understanding of the effects of the molecule itself. For the Cybin team, this decision represents a further opportunity to help millions of sufferers of these all-too-prevalent disorders.” SAD, sometimes called social phobia, is categorized as the persistent and irrational fear of embarrassment and humiliation in social situations, and it is estimated to impact 3% to 7% of adults in the United States. The disorder often begins in childhood or adolescence and can contribute to major depression, substance abuse and other mental health problems. The disorder can be associated with extensive functional impairment and reduced quality of life. An estimated 3% to 6% of the U.S. adult population suffers with GAD, experiencing excessive anxiety and worry (apprehensive expectation) about a range of everyday topics/events. The disorder is one of the most common mental disorders identified in both community and clinical settings and is associated with increased use of health care services. “Based on estimates derived from currently available FDA-approved treatments, the current U.S. market is estimated at $165M with global estimates at $1.15B as of 2021,” the company announced. “The market is currently made up of multiple approved drugs still under patent protection, generics and off label use drugs. For the gad market, “current global estimates are approximately $2.99 billion and projected to grow to $4.5B by 2027,” the announcement continued. “The market is currently made up of multiple approved drugs still under patent protection, generics and off label use drugs, including benzodiazepines that carry a risk of addiction, misuse and dependence. The World Health Organization (“WHO”) estimates that 1 in 13 adults globally suffers from anxiety; however, current FDA-approved medications for anxiety disorders have slow onset of action with side effects that include weight gain, nausea, vomiting and sexual dysfunction. What’s more, many patients see no benefit from the treatments. However, studies evaluating the treatment of anxiety with psychedelics indicate a significant response to therapy, including a faster onset of action with less addictive effects. “People struggle with many different mental health challenges, but anxiety affects more people than any other,” explained Cybin chief clinical officer Dr. Alex Belser. “With the advent of the COVID-19 pandemic, rates of anxiety have increased threefold, leaving many folks in a debilitating state. We think that treatment with psychedelic medicine may help. “Our team’s previous research on anxiety at New York University and the trials conducted at UCLA and Johns Hopkins showed large magnitude decreases in anxiety after treatment with psychedelic-assisted psychotherapy,” he continued. “This is a promising approach to treat anxiety with a clear pathway.” Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Energy Fuels is making major strides toward restoring critical U.S. rare earth supply chains
• No other U.S. company is producing a product this far down the rare earth value chain
• Company working to transform into ‘America’s Critical Mineral Hub,’ with the main focus being on the White Mesa Mill

As the U.S. government appears to be throwing support and assistance behind efforts to limit its dependence on other countries for the mining and production of various metals, Energy Fuels (NYSE American: UUUU) (TSX: EFR) is increasing its efforts to produce commercial rare earth elements (“REEs”), as well as continue its commitment to uranium production, recycling and environmental and social responsibility (https://ibn.fm/XBT1k). “Without a doubt, Energy Fuels is making major strides toward restoring critical U.S. rare earth supply chains, while also maintaining our position as the leading U.S. uranium producer,” said UUUU’s president and CEO Mark S. Chalmers. “On rare earths, our efforts over the past several months culminated in the announcement on March 1 that Energy Fuels and Neo Performance Materials were creating a new, U.S.-European rare earth supply chain. “In early March, we began to receive shipments of rare-earth-rich natural monazite sands from Chemours’ Georgia heavy mineral sand operations,” he continued. “In late-March, we began to ramp-up production of an intermediate rare earth product at our White Mesa Mill in Utah using monazite from Chemours. This is expected to be a high-value product ready to be separated and refined into value-added rare earth products at Neo’s plant in Europe. At this time, no other U.S. company is producing a product this far down the rare earth value chain.” Energy Fuels first announced its intended entry into the REE sector in April 2020 (https://ibn.fm/j2viA). The company made the decision to enter the space after months of deliberate review and testing, including discussions with various technical experts and the U.S. government. The company noted at the time that the U.S. government was actively seeking a domestic source of REE minerals, which are needed for national defense. Energy Fuels identified its Utah-based White Mesa Mill as uniquely suited to potentially receive and process a certain type of ore called monazite for the recovery of REEs, along with uranium. Since that time, the company has identified and reached a series of essential landmarks on the journey to becoming a key producer of REEs. “However. . . we have much bigger rare earth plans, and the momentum is building rapidly as we execute our purposeful strategy,” said Chalmers. “We are now taking real steps toward designing and building fully integrated, U.S. rare earth production capabilities. . . . We continue to believe Energy Fuels has distinct advantages in the rare earth sector. Monazite ore has superior distributions of the high-value magnetic rare earths, including NdPr and ‘heavy’ rare earths, versus most other rare earth minerals mined around the world, and monazite is currently produced as a byproduct of existing heavy mineral sand operations. We are also taking steps to utilize licensed and existing facilities at the White Mesa Mill to process the monazite into value-added products. This is a highly capital efficient initiative. “At the same time, we are transforming our company into ‘America’s Critical Mineral Hub,’ with the main focus being on the White Mesa Mill in Utah,” conclude Chalmers. “While nearly all current and future nuclear reactors are fueled by uranium, other clean energy and advanced technologies, including electric vehicles renewable energy and batteries, require other critical minerals that Energy Fuels produces. A robust market for responsibly produced, American clean energy products and technologies, made by American workers, is possible in the U.S.” For more information, visit the company’s website at www.EnergyFuels.com. NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• WTER to join Russell Microcap Index effective June 28, 2021
• Addition to prestigious microcap Index will only heighten awareness of WTER stock on Wall Street
• Membership in Russell Microcap Index includes automatic listing in other appropriate growth and value style indexes

The country’s largest independent alkaline water company, The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), will join the Russell Microcap(R) Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28, 2021 (https://ibn.fm/yyHMg). The Russell indices are heavily used and relied on by investment managers as well as institutional investors. “We are honored to be included in the Russell Microcap Index,” said WTER president and CEO Richard A. Wright. “Joining the Nasdaq exchange two and a half years ago brought our company visibility in the investment community. Our addition to the Russell Microcap Index will only heighten the awareness of our stock on Wall Street.” Russell indexes are part of FTSE Russell, a leading index provider known for providing critical innovative benchmarking, analytics and data solutions for investors around the world. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries; its indexes cover 98% of the global investable market. WTER noted that an estimated $10.6 trillion in assets are benchmarked against Russell’s US indexes. Along with membership in the Russell Microcap Index comes automatic inclusion in other appropriate growth and value style indexes. Membership in those indexes is determined by FTSE Russell based on objective, market-capitalization rankings and style attributes. The Alkaline Water Company’s inclusion in these indexes is clear evidence of its success in building a strong, successful beverage portfolio that includes Alkaline88(R), known for its superior hydration with a perfect 8.8pH balance; A88 Infused(R), which includes flavored waters and CBD waters; and A88CBD(TM), a line of CBD ingestibles and topicals. The company is dedicated to purity, quality, value and taste, and is focused on making a difference in the water people drink. “According to Nielsen for the 52 weeks ending 4/24/21, we continued to outperform the category over 2x in sales volume and over 13x in unit volume,” said Wright. “We are now the largest independent alkaline water company in the country, and we are seeing accelerated growth in our single-serve, aluminum and flavored waters. Our clients, consumers and shareholders are all important to us, and we’re working hard to add value for each of them.” For more information, visit the company’s website at www.TheAlkalineWaterCo.com and www.a88CBD.com. NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER

• More than 3,200 pharmaceutical and biotech companies, plus government and academic organizations attended latest BIO Conference
• Predictive Oncology’s Helomics, TumorGenesis, Soluble Biotech all attended the virtual conference from June 14-18, 2021
• Companies leveraged different components of the conference to entertain new partnerships or customers

Every industry has a revolving calendar of events, but some are “must attends” due to their global reach and prospective deal flow, like conferences put on by Biotechnology Innovation Organization, or just “BIO” as it’s known. This year, three wholly owned subsidiaries of Predictive Oncology (NASDAQ: POAI) – Helomics, TumorGenesis and Soluble Biotech – attended BIO DIGITAL, a premier international biotech partnering event held virtually on June 10-11 & 14-18, 2021. The Predictive Oncology companies attended the event during the second leg of the conference. BIO is the world’s largest advocacy association representing member companies, state biotechnology groups, academic and research institutions, and related organizations across the U.S. and in 30+ countries. This year’s virtual conference attracted more than 3,200 pharmaceutical and biotech companies, in addition to government and academic organizations. Each year, the BIO events feature presentations from key opinion leaders and some of the world’s brightest scientific minds discussing the latest breakthroughs in medicine. While informative, the thrust of attending for companies like that of Predictive Oncology is networking and one-on-one sessions that can result in new partnerships or customers. “In previous conferences Soluble Biotech has typically received more than a dozen requests for proposals, leading to new contracts for their main service of providing protein therapeutic formulations (i.e., formulations for vaccines, antibodies, virus-like particles),” said Predictive Oncology CEO J. Melville Engle. He added that the Helomics unit is leveraging BIO’s one-on-one sessions to showcase its precision medicine discovery platform branded “PeDAL” (https://ibn.fm/To6tz). PeDAL, an acronym for Patient-centric Drug Discovery using Active Learning, is a unique technology that combines a proprietary, clinically-validated tumor profiling assay, a knowledgebase of proprietary and public data together with active learning. The active learning allows for the efficient exploration of drug responses against a large diverse patient biology “space.” The conference allowed TumorGenesis to market its products and services specialized on culturing cancer cells from ovarian and breast cancers that more accurately mimic a patient’s tumors. TumorGenesis technology effectively “fools” ovarian cancer cells into growing outside the body, where they can be studied to better understand the efficacy and safety of cancer drugs specific to the patient. These improved ex-vivo tumor models can then be used by researchers to investigate cancer and by clinicians to develop patient-specific treatment plans. Engle summed up the comprehensiveness of POAI’s divisions in saying, “Our unique approach allows Pharma therapeutic groups to see how we embrace the complexity and diversity of patient tumors in a highly-scalable and efficient experimental exploration of drugs and drug combinations for patient-specific populations.” And, thanks to organizations like BIO, all the companies’ utility and value can be showcased at global scale. For more information, visit the company’s website at www.Predictive-Oncology.com. NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Emaginos has built a system that transforms schools using a model that perfectly meets the demands the pandemic exposed
• DLS offers systemic transformation to a K-12 public education system that encourages and fosters students’ desire to learn
• The company is raising capital for further development and placement of its transformational public school model

Like so many other educational entities, Emaginos Inc. has been deeply impacted by COVID-19. Unlike many other educational organizations, Emaginos — and its Discovery Learning System — is perfectly prepared for the changes that the global pandemic has forced upon a generation of K-12 students struggling to find the most effective way to learn. Emaginos is a REG-A company with news posted on Yahoo Finance in the business of transforming K-12 public education; see the website if interested in investing. “COVID-19 has created a teachable moment for Emaginos,” said Emaginos president Allan Jones in an open letter to educators (https://nnw.fm/DsAtq). (https://ibn.fm/CJP2q). “Social distancing forced K-12 education leaders to adopt new ways for teachers to teach and students to learn. Serendipitously, Emaginos has built a Discovery and Learning system (‘DLS’) that transforms schools using a model that perfectly meets the demands the pandemic exposed. COVID did not create the needs. They were already there, hidden beneath decades of traditional educational pedagogy. The Emaginos model was an idea in search of its time.” A teachable moment, explains Jones, “is that wonderful time when the student wants to learn what the teacher wants to teach.” In this instance, Emaginos is always ready to learn and grow as it leads the way forward in transforming education. The Emaginos Discovery Learning System offers a systemic transformation from the current teacher-centered model to a K-12 public education system that encourages and fosters students’ desire to learn. The company is in the process of raising capital for further development and placement of its transformational public school model. While now is a critical moment for Emaginos as it launches its exclusive DLS model into the educational space, it is also a critical moment for those looking to become involved in companies, projects and ideas with the potential to make a profound impact on the world. Emaginos is the first company with an actionable plan to transform and improve public schools rather than replace them (https://nnw.fm/1wUQM). (https://ibn.fm/yFInO). The Emaginos model utilizes existing funding, facilities and staff to improve educational approaches and outcomes, in many cases savingschool districts money as they subscribe to and implement the Emaginos platform. “Good teachers know how to recognize [teachable] moments and take advantage of them,” Jones points out in his open letter. “Great teachers know how to create them.” Emaginos is seizing an opportunity to provide the tools that empower great teachers as they strive to fill each school day with teachable moments that constantly challenge, inspire and support students. For more information about Emaginos and to learn about investment and shareholder opportunities, visit www.Emaginos.com. NOTE TO INVESTORS: The latest news and updates relating to Emaginos are available in the company’s newsroom at https://nnw.fm/Emaginos https://ibn.fm/Emaginos

• GPFT customers can convert crypto of choice at checkout to make online purchases.
• Announcement demonstrates company’s outreach to growing demographic of early adopters, younger buyers.
• Grapefruit is building a well-earned reputation for pioneering future-looking ideals and products.

In an industry known for embracing the use of cryptocurrency (https://ibn.fm/14OmW), Grapefruit USA (OTCQB: GPFT) joined other leaders in the cannabis space in paving the way forward when it announced that it is accepting cryptocurrency as payment on its recently launched e-commerce store (https://ibn.fm/ymP2R). The company noted that its customers who prefer Bitcoin, Ether, Bitcoin Cash, Litecoin, Dogecoin or Monero will now be able to “convert” their crypto of choice at checkout to make online purchases. “Grapefruit’s THC-free hemp-derived CBD Hourglass technology-driven products, just like cryptocurrencies and the blockchain, are the future, and Grapefruit’s acceptance of crypto as payment demonstrates GPFT’s outreach to the explosively growing demographic of crypto early adopters and other ‘younger’ buyers who also seek the holistic benefits of Grapefruit’s THC-free, hemp-derived Hourglass time-release CBD products,” said Grapefruit CEO Bradley J. Yourist. “Everyone, young and old, experiences sore muscles from working out and other aches and pains, and our THC-free hemp-derived CBD Hourglass-powered products can provide a solution for all demographics — whether they choose to pay by American Express Platinum or Dogecoin on our accurate and secure payment platform. “We envision the days after Sen. Schumer succeeds in his efforts to decriminalize THC, and customers from the 50 states and throughout the world will be able to use crypto to pay for purchases of our full-spectrum THC Hourglass time-release technology-powered products through our e-commerce platform,” Yourist continued. As Yourist alluded, Grapefruit is building a well-earned reputation for pioneering future-looking ideals and products. The company’s flagship product features cutting-edge science and technology that solves the age-old problem of THC and other cannabinoids not being easily absorbed through the skin. Grapefruit’s Hourglass topical cream uses patented microsized particles to slowly deliver THC and a wide range of cannabinoids through skin topical administration. No other topical cream product on the market provides users with the holistic benefits of the range of cannabinoids found in Hourglass, including THC+CBD, CBN, CBG, Delta8, THCV and CBE. The development of Hourglass and the acceptance of crypto are symbolic of Grapefruit’s commitment to being a leader in the cannabis industry by using science and technology to create truly disruptive products for both the recreational and medicinal cannabis marketplaces.  The company is focused on delivering patented cannabis and hemp-derived products that fundamentally change the way consumers use THC, CBD and hemp. Grapefruit is devoted to selling only the highest-quality, plant-based, independently tested and reliable cannabis and hemp products and will make no claims unless clinically validated. All products marketed and sold on the company’s new e-commerce website will be thoroughly tested and include a QR-coded certificate of analysis, which will provide consumers with a complete list of third-party-verified ingredients certifying each product’s cannabinoid content, purity and safety. In addition, the company does not recommend investing in cryptocurrencies without doing due diligence and obtaining the advice of an investment advisor or other counsel. To find out more about the company and its game-changing Hourglass time-release cannabinoid delivery cream, please visit www.GrapefruitBlvd.com. NOTE TO INVESTORS: The latest news and updates relating to GPFT are available in the company’s newsroom at https://ibn.fm/GPFT